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The P7C3 class of aminopropyl carbazole chemicals
fosters the survival of neurons in a variety of rodent
models of neurodegeneration or nerve cell injury. To
uncover its mechanism of action, an active derivative
of P7C3 was modified to contain both a benzophe-
none for photocrosslinking and an alkyne for CLICK
chemistry. This derivative was found to bind nico-
tinamide phosphoribosyltransferase (NAMPT), the
rate-limiting enzyme involved in the conversion of
nicotinamide into nicotinamide adenine dinucleotide
(NAD). Administration of active P7C3 chemicals to
cells treated with doxorubicin, which induces NAD
depletion, led to a rebound in intracellular levels of
NAD and concomitant protection from doxorubicin-
mediated toxicity. Active P7C3 variants likewise
enhanced the activity of the purified NAMPT enzyme,
providing further evidence that they act by increasing
NAD levels through its NAMPT-mediated salvage.INTRODUCTION
No substantive therapeutics are available for the treatment of
almost any form of disease entailing nerve cell death. Patients
suffering from any of a wide spectrum of neurodegenerative
diseases, including Parkinson’s disease, Alzheimer’s disease,
amyotrophic lateral sclerosis, fronto-temporal dementia, and
Huntington’s disease are condemned to progressive demise
of the CNS by virtue of nerve cell death. It is likewise the
case that no effective treatments exist for injuries to the brain
or peripheral nervous system, including traumatic or concus-
sive brain injury, spinal cord injury, or peripheral nerve injury.
Any chemical having the capacity to safely impede nerve cell
death in the context of these varied diseases or injuries would1324 Cell 158, 1324–1334, September 11, 2014 ª2014 Elsevier Inc.offer the opportunity for transformative impact in modern
medicine.
Previously, we performed a target-agnostic, in vivo screen in
search of chemicals that might enhance hippocampal neurogen-
esis in adult mice (Pieper et al., 2010). The screen was simple
in concept. We selected 1,000 drug-like chemicals from the
250,000 compounds in the University of Texas Southwestern
Medical Center (UTSWMC) high-throughput screening center.
The compounds were selected to preserve chemical diversity,
enhance the representation of chiral molecules, and avoid unto-
ward chemical properties such as reactive moieties. The 1,000
molecules were randomly pooled into groups of ten, and each
pool was administered directly into the left ventricle of two adult
mice. Intracranial delivery was facilitated by stereotactic posi-
tioning of a canula fed directly by an Alzet minipump containing
themixture of ten chemicals. The drugmixture was administered
over a week-long period at concentrations anticipated to deliver
midnanomolar levels of the ten test compounds. Daily injections
of the thymidine analog, bromodeoxyuridine (BrdU), were coad-
ministered in order to monitor the formation of new hippocampal
nerve cells. Following compound administration, animals were
sacrificed such that brain tissue could be recovered, sectioned,
and stained with antibodies to BrdU. This 2-year screen led to
the discovery of a handful of pools that enhanced neurogenesis
in both test mice that had been exposed to the pool. Breakdown
of the active pools allowed the individual testing of each of the
ten chemicals in the pool, leading to the discovery of eight pro-
neurogenic compounds (Pieper et al., 2010).
Among the eight proneurogenic chemicals, pharmacological
testing gave evidence that only one of the compounds had favor-
able pharmacological properties. Pool seven (P7) contained an
aminopropyl carbazole as its active, third compound (C3).
When administered to mice via intraperitoneal, intravenous, or
oral routes, the P7C3 compound revealed favorable half-life, vol-
ume of distribution, and brain penetration. It was also found that
P7C3 could be safely administered to mice and rats for pro-
longed periods at concentrations well above those required to
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Figure 1. Protection of Cultured U2OS Cells from Doxorubicin-
Mediated Toxicity by Active Derivatives of P7C3
(A) U2OS cells were treated with 5 mM P7C3-A20 for 2 hr prior to incubation
with the indicated concentrations of doxorubicin for 72 hr.
(B) Comparison of the P7C3-S243 enantiomers in protection of cells from
doxorubicin revealed that ()-P7C3-S243 was more active than (+)-P7C3-
S243, consistent with their respective neuroprotective activities in vivo (see
text). In all cell survival graphs, data are expressed as mean ± SD of experi-
mental duplicates.
See also Figures S1, S2, and S3 and Tables S1 and S2.stimulate hippocampal neurogenesis, giving evidence that the
molecule was not overtly toxic to rodents.
Although it was initially anticipated that proneurogenic com-
pounds would act by stimulating the mitotic birth of newborn
nerve cells in the subgranular layer of the dentate gyrus, P7C3
revealed no such activity. The 2-fold enhanced level of BrdU-
positive neurons observed over a week-long dose of P7C3
was absent when animals were pulsed with BrdU for only
24 hr. More strikingly, when BrdU was pulsed for only 1 day
and animals were subsequently administered P7C3 for 1 month,Cwe observed a far larger enhancement in BrdU-positive hippo-
campal neurons (500%). Instead of stimulating the mitotic divi-
sion of neuronal stem cells, these observations gave evidence
that P7C3 mitigated the death of newborn neurons. Under the
conditions of our study, only 10%–20%of newborn neurons sur-
vive the month-long differentiation process to become properly
wired hippocampal neurons. Prolonged administration of P7C3
significantly mitigated the death of newborn neurons, such that
upward of half of the cells survive themonth-long ‘‘differentiation
gauntlet’’ taking place between stem cell mitosis and terminal
nerve cell differentiation. Indeed, localized expression of proap-
optotic proteins in newborn neurons has been found to limit
neurogenesis, whereas expression of antiapoptotic proteins en-
hances neurogenesis in adult mice (Kim et al., 2009; Kuhn et al.,
2005; Sun et al., 2004). It has likewise been found that the
proneurogenic benefits of wheel running and/or enriched envi-
ronment for caged rodents is primarily attributable to neuropro-
tective effects on newborn hippocampal neurons (Kempermann
et al., 1997; Kim et al., 2010; van Praag et al., 1999).
Having discovered the aminopropyl carbazole chemical in an
unbiased, in vivo screen and having found that it protects
newborn neurons from death, we use methods of medicinal
chemistry to improve the potency and pharmacological proper-
ties of P7C3 (MacMillan et al., 2011; Naidoo et al., 2014; Pieper
et al., 2014). Using these improved, active derivatives of P7C3,
we have observed neuroprotective activity in animal models of
Parkinson’s disease (De Jesu´s-Corte´s et al., 2012), amyotrophic
lateral sclerosis (Tesla et al., 2012), as well as concussive injury
to the rodent brain (Yin et al., 2014). Of significant concern, how-
ever, was the fact that we have been ignorant of the mechanism
of action of the P7C3 class of neuroprotective chemicals. Here,
we provide evidence that these chemicals function by enhancing
the activity of the rate-limiting enzyme in the salvage of nicotin-
amide adenine dinucleotide (NAD) from nicotinamide.
RESULTS
Active Variants of P7C3 Protect Cultured Cells from
Doxorubicin-Mediated Toxicity
Progress on studies aimed toward resolving the mode of action
of P7C3 has been hampered by the fact that we have been
limited to studies of drug action in living animals. Our standard
assay of neurogenesis requires, under optimal conditions, a
1 month turnaround from the synthesis of a new derivative to a
score for its neuroprotective activity. In efforts to break this
logjam, we tested whether P7C3 might have cell-protective
activity to any of eight generic toxins. The active A20 variant of
P7C3 was found to protect cultured U2OS cells from doxoru-
bicin-mediated toxicity (Figure 1A). By contrast, no evidence of
drug-mediated protection was observed for any of seven other
toxins (Figure S1 available online). Furthermore, as judged by
the DNA damage marker—phosphorylation of H2AX and the
hallmark of apoptosis—caspase-3 activation, coadministration
of A20 blocked doxorubicin-induced apoptosis, but not DNA
damage response (Figure S2).
In order to assess whether a correlation might exist between
proneurogenic activity in living mice and doxorubicin toxicity
(dox:tox) protection, we assayed 224 compounds that haveell 158, 1324–1334, September 11, 2014 ª2014 Elsevier Inc. 1325
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Figure 2. Identification of the P7C3-Binding
Protein p70 Using the P7C3-S326 Photo-
crosslinking Probe
(A) Chemical structure of P7C3-S326.
(B) Full gel image of photocrosslinking in H2122
cells with P7C3-S326 followed by click chemistry
with Alexa 532 dye. The active analog P7C3-A20
competed away the UV-dependent binding of p70
to P7C3-S326. See also Figure S4.
(C) Formulas used for calculating doxorubicin
toxicity (dox:tox) protection activity. Protection
activity is expressed by (Sinf-S0)/AC50 in the 12-
point dose response curve (DRC) corresponding
to each compound, wherein both efficacy and
potency of compounds were considered. Sinf
represents the expectedmaximal protection. S0 is
the baseline. AC50 is the concentration of a
compound where 50% of its maximal protection
effect was observed. See also Figure S3 and
Table S2.
(D) Scatterplot of 168 derivatives of P7C3 revealed
a significant correlation between protective activ-
ity of P7C3 analogs from doxorubicin-mediated
toxicity and their ability to compete for photo-
crosslinking of P7C3-S326 to p70. In the photo-
crosslinking assays, the p70 band intensity was
quantified by Image J and compared the sample of
P7C3-S326 alone with that of P7C3-S326 plus
competitor. Pearson correlation coefficient (r) and
two-tailed p value were determined by GraphPad
Prism 6 and Spearman Rank Correlation (v1.0.1)
software. See also Table S1.been synthesized and assayed for proneurogenic activity over
the past 4 to 5 years (Table S1). These include hundreds of struc-
ture:activity relationship derivatives of P7C3, as well as a number
of tricyclic antidepressants reported in the literature to have pro-
neurogenic activity (Malberg et al., 2000). P7C3 derivatives were
the only molecules having dox:tox protective activity (Figure S3;
Table S2). Further inspection of the data revealed that the chem-
ical features of the carbazole ring, length of the aliphatic linker,
and nature of the aromatic ring were all important determinants
for both proneurogenic activity and dox:tox protection. Perhaps
most compellingly, it was observed that the ()-P7C3-S243
enantiomer that was active in the in vivo neurogenesis assay
(Naidoo et al., 2014), the 1-methyl-4-phenyl-1,2,3,6-tetrahydro-
pyridine (MPTP) model of Parkinson’s disease (Naidoo et al.,
2014), and the concussive blast injury model (Yin et al., 2014)
was also protective in the dox:tox assay (Figure 1B). By contrast,
the (+)-P7C3-S243 enantiomer that was far less active in the
three in vivo assays of neuroprotection was also considerably
less active in the dox:tox protection assay. From these observa-
tions, we conclude that active derivatives of P7C3 function by a
related mechanism to protect neurons in living animals as well as
cultured U2OS cells exposed to doxorubicin.
Identification of p70 and p55 as Intracellular Targets
of P7C3
Various methods have been employed in efforts to identify the
intracellular target of P7C3, including biotinylation followed by1326 Cell 158, 1324–1334, September 11, 2014 ª2014 Elsevier Inc.affinity purification, radiolabeling followed by filter-binding
assays, and photocrosslinking. Among these strategies, the
photocrosslinking approach has been uniquely successful.
P7C3-S326 was prepared to contain both a benzophenone for
photocrosslinking and an alkynemoiety for use in click chemistry
(Figure 2A). This derivative was found to be active in both the
in vivo neurogenesis assay and the dox:tox assay. When incu-
bated with cultured cells, the P7C3-S326 derivative became
covalently attached to roughly a dozen proteins. Among the
covalently modified proteins, only one could be competed
when the cells were coincubated with a 303 excess of the active
A20 variant of P7C3. This polypeptide exhibited an apparent
molecular mass of 70 kD (Figure 2B).
Binding competition assays were conducted with 168 chemi-
cal derivatives of P7C3 as a means of testing whether there
might be a correlation between dox:tox protection and binding
competition (Figure S4). The scatter plot shown in Figure 2D
revealed a statistically significant correlation between the two
activities, yielding a p value of 9.4 3 1020. It can thus be pre-
dicted with a high level of confidence that active variants of
P7C3 are able to compete for P7C3-S326 crosslinking but that
inactive variants cannot. Armed with this knowledge, cell frac-
tionation experiments were performed in order to enrich for the
p70 band. During the course of these studies, it was periodically
observed that P7C3-S326 could also be crosslinked to a second
band running with an apparent molecular weight of 55 kD. Just
as was the case for p70, active variants of P7C3 competed for
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Figure 3. Identification of p70 and p55 Tar-
gets of P7C3 by 2D Gel Electrophoresis
and Mass Spectrometry
Lysates from cells exposed to 0.3 mM P7C3-S326
were CLICKed with a green dye, Alexa 532, and
those from cells coexposed to 0.3 mM P7C3-S326
and 5 mM of the active competitor P7C3-A20 were
CLICKed with a red dye Cy5.
(A and B) CLICK-reacted lysates were combined,
subjected to 2D gel electrophoresis, and scanned
in the green channel (A) and the red channel (B).
(C) Images from both channels were merged to
reveal green-only spots.
(D) After spot picking, total proteins were visual-
ized by Sypro Ruby staining. White circles indicate
spots excised for shotgun mass spectrometry
analysis.
See also Table S3.p55 binding, whereas inactive variants did not. Moreover, both
proteins copurified with a cellular fraction following centrifuga-
tion at 12,000 g.
The p70 and p55 Targets of P7C3 Correspond to
Nicotinamide Phosphoribosyltransferase
Partially purified protein preparations were resolved by 2D gel
electrophoresis. In order to discriminate between protein spots
competed by an excess of the active, A20 variant of P7C3 and
those that were not, separate lysates were prepared from cells
that had been coexposed to the P7C3-A20 competitor or not.
Click chemistry was used to append a red fluorescent dye
onto P7C3-S326-modified proteins of the former lysates (Kolb
et al., 2001). The latter lysates were modified by a green dye,
such that in imaging 2D gels, we could focus on green protein
spots and avoid spots labeled by both green and red dyes.
Such efforts led to the identification of green-only spots
migrating at either 70 kD or 55 kD (Figures 3A–3C). Proteins of
both molecular weights migrated in the isoelectric focusing
dimension at four closely spaced pH positions. This electropho-
retic behavior might be consistent with posttranslational modifi-
cations of the same protein, leading to different isoforms bearing
slight differences in ionic charge. Perplexingly, the pattern of
charge distribution was identical for the 70 kD and 55 kD
polypeptides.
The eight green-only spots, four from p70 and four from p55,
were then picked and subjected to shotgun mass spectrometry
for protein identification. All four of the p55 spots yielded by far
the highest number of spectral counts for nicotinamide phos-
phoribosyltransferase (NAMPT) (Table S3). Both the predicted
size (55 kD) and isoelectric point (pH 6.7) of NAMPTmatch spots
1–4 picked from the 2D gel. Likewise, mass-spectrometry-based
analysis gave substantive percentage coverage levels of 12%,
82%, 38%, and 62% for the NAMPT enzyme in spots 1–4 (Table
S3). By contrast, no proteins could be identified above the false
discovery rate for the four p70 spots. Poststaining of the 2D gelCell 158, 1324–1334, Sepwith Sypro ruby dye showed prominent
protein staining for all four of the p55
spots and no staining for any of the fourp70 spots (Figure 3D). Apparently, despite equivalent photocros-
slinking by P7C3-S326, the molar ratio of drug modification of
p70 must be at least three orders of magnitude greater than p55.
The perplexing relationship between p70 and p55was clarified
upon adding 7 M urea to the SDS-PAGE gels used to resolve the
two bands. In the absence of urea, almost all of the S326-modi-
fiedmaterial migrated as the p70 band. Addition of urea to the gel
converted all of the labeled material to the p55 band (Figure 4A).
By running a gel crafted to contain a horizontal gradient of
urea, 7 M on the right and no urea on the left, it was possible
to observe graded conversion of p70 into p55 (Figure 4B). These
observations give evidence that, when NAMPT is covalently
bound by P7C3-S326, it can adopt an anomalous pattern of
electrophoretic migration under gel conditions that are not fully
denaturing.
Active Derivatives of P7C3 Restore NAD Levels in
Doxorubicin-Treated Cells
Having observed P7C3-S326 crosslinking to both the p70 and
p55 forms of NAMPT, we wondered whether active variants of
P7C3 might modify the activity of the enzyme. The NAMPT
enzyme controls the rate-limiting step in the NAD salvage
pathway (Preiss and Handler, 1958). NAMPT is an obligate dimer
whose molecular structure has been resolved by X-ray crystal-
lography (Khan et al., 2006; Wang et al., 2006). On the basis of
molar ratio of crosslinking, P7C3-S326 strongly prefers the p70
isoform of NAMPT relative to the p55 isoform. Hypothesizing
that p70 represents a drug-altered form of NAMPT, we tested
whether the highly active P7C3-A20 variant might either enhance
or reduce NAD levels in living cells.
Doxorubicin is a DNA-damaging toxin known to activate the
poly-ADP-ribose polymerase (PARP) enzyme as a central feature
of DNA repair (Mun˜oz-Ga´mez et al., 2009; Pacher et al., 2002).
PARP uses NAD as the donor for poly-ADP-ribose synthesis
and hence lowers cellular levels of NAD. U2OS cells exposed
to sublethal levels of doxorubicin were subjected to metabolitetember 11, 2014 ª2014 Elsevier Inc. 1327
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Figure 4. Conversion of p70 into p55 in the Presence of Urea
(A) CLICK-reacted lysates from H2122 cells treated with P7C3-S326 were
separated on a standard 8% SDS-PAGE gel (left) or one supplemented with
7 M urea (right) and visualized on a Typhoon scanner. Asterisk indicates the
crosslinked protein that migrates as 70 KDa in a standard SDS-PAGE gel and
55 KDa in the SDS-PAGE gel supplemented with 7 M urea.
(B) The same lysates were resolved on a horizontal urea gradient gel coloaded
with crosslinked p70 and the same 75 kD and 50 kD size standard proteins
displayed in (A). The horizontal urea gradient proceeds from zero denaturant
on the left to 7 M denaturant on the right.analysis bymass spectrometry, allowing simultaneous, quantita-
tive analysis of hundreds of intracellular metabolites (Tu et al.,
2007; Wang et al., 2009). As expected, doxorubicin treatment
led to a significant decline in NAD levels relative to all other
metabolites assayed. Coadministration of the A20 variant of
P7C3 led to a dose-dependent replenishment of NAD (Figure 5A).
The mass spectrometry methods used to quantitate metabolite
levels measured NAD relative to hundreds of other intracellular
metabolites. As such, the ability of the A20 variant of P7C3
to restore intracellular levels of NAD does not simply reflect the
generalized health of cells but instead reflects the relative
increase in NAD levels compared with hundreds of other
metabolites.
A more facile method of quantifying the NAD analyte, employ-
ing the commercially available ‘‘NAD/nicotinamide adenine
dinucleotide, reduced form (NADH)-Glo’’ kit, confirmed P7C3-
A20-mediated rebound of NAD levels in doxorubicin-treated
U2OS cells. We also observed NAD rebound for the racemic
mix of the active P7C3-S243 compound but no rebound at all
for the inactive P7C3-S6 and P7C3-S117 compound variants
(Figure 5B). This method of assay was used to test 159 variants
of P7C3 that had been used to query the correlative relationship1328 Cell 158, 1324–1334, September 11, 2014 ª2014 Elsevier Inc.between dox:tox protection and competition in the P7C3-S326
crosslinking assay (Table S1; Figure 2D). Each chemical variant
of P7C3 was coincubated with doxorubicin on cultured U2OS
cells at five doses, and cells were assayed for intracellular levels
of NAD (Figure S5; Table S2). The scatterplot shown in Figure 5C
reveals exceptional concordance between the dox:tox protec-
tive activities of the 159 compounds and their relative abilities
to enhance NAD levels (correlative p value of 1.8 3 1035).
NAMPT is the rate-limiting enzyme in the salvage pathway
whereby cells sequentially convert nicotinamide into nicotin-
amide adenine mononucleotide (NMN) and NAD (Preiss and
Handler, 1958). If active variants of P7C3 indeed bind to the
NAMPT dimer in a manner fostering its activity, then these com-
pounds should enhance the flux of nicotinamide through the
salvage pathway. To test this hypothesis, 14C-labeled nicotin-
amide was administered to cultured U2OS cells that were
pretreated with doxorubicin and assayed by thin-layer chroma-
tography followed by autoradiography. As shown in Figure 6,
enhanced conversion of radiolabeled nicotinamide into NMN
and NAD was observed in a dose-responsive manner upon
exposure of cultured U2OS cells to the active, A20 variant of
P7C3. Upon examining if P7C3 derivatives might elevate NAD
levels in naive cells (without doxorubicin pretreatment), we failed
to observe any compound-mediated effect on NAD levels.
Active Variants of P7C3 Enhance the Activity of the
Purified NAMPT Enzyme
A recombinant form of the human NAMPT enzyme was cloned,
expressed, and purified according to published conditions
(Khan et al., 2006; Wang et al., 2006). The enzymatic activity of
recombinant NAMPT was monitored in a coupled assay wherein
nicotinamide conversion to NMN was followed by sequential
production of NAD (via the nicotinamide mononucleotide
adenylyl-transferase [NMNAT] enzyme) and NADH (via alcohol
dehydrogenase). As shown in Figure 7A, the A20 variant of
P7C3 activated the enzyme reaction in a dose-dependent
manner. No activation of NADH production was observed
when NAMPT was eliminated from the reaction, giving evidence
that enhancement did not result from compound effects on
either NMNAT or alcohol dehydrogenase (Figure S6).
Two additional experiments were conducted to investigate
activation of the recombinant NAMPT enzyme. First, 30 deriva-
tives of P7C3 having varied activity were tested for enzyme acti-
vation. The ability of the 30 variants to activate NAMPT in the
coupled enzyme assay was then correlated on scatter plots to
three other measures of compound activity: (1) ability to protect
cultured cells from doxorubicin toxicity; (2) ability to compete
with photocrosslinking by P7C3-S326 in living cells; and (3) abil-
ity to restore NAD levels in doxorubicin-treated cells (Figure 7B).
In all cases, statistically significant evidence of correlation was
observed. Second, we compared the activities of the racemic
mix of P7C3-S243, the ()P7C3-S243 enantiomer and the
(+)P7C3-S243 enantiomer in NAMPT enzyme assay. As shown
in Figure 7C, the ()P7C3-S243 enantiomer was more active in
stimulating NAMPT than the racemix mix, which—in turn—was
more active than the (+)P7C3-S243 enantiomer. This same hier-
archy of activity has been observed in all in vivo assays tested to
date, including adult neurogenesis, and the MPTP model of
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Figure 5. Active Variants of P7C3 Compen-
sate NAD Exhaustion Induced by Doxoru-
bicin
(A) U2OS cells were treated with the indicated
concentration of P7C3-A20. Cells were harvested,
and NAD metabolites were measured by liquid
chromatography-tandem mass spectrometry.
Abundance of NAD was normalized relative to
total metabolites (Experimental Procedures). The
data are represented as the mean ± SD of exper-
imental duplicates.
(B) Active derivatives P7C3-A20 and P7C3-S243,
but not inactive derivatives P7C3-S6 or P7C3-
S117, facilitate replenishment of NAD levels in
doxorubicin-treated cells. Cells were grown in 96-
well plates and treated with the indicated con-
centrations of P7C3-A20, P7C3-S243, P7C3-S6,
or P7C3-S117 together with 0.5 mM doxorubicin
for 45 hr. Cellular NAD abundance was deter-
mined by NAD/NADH Glo assay kit. The data are
represented as the mean ± SD of experimental
duplicates. See also Figure S5 and Table S2.
(C) Scatterplots revealed a strong correlation be-
tween dox:tox protective activities of 159 com-
pounds and their relative abilities to replenish NAD
levels. The activities in both assays are repre-
sented by (Sinf-S0)/AC50 in dose response curves
of test compounds.
See also Table S1.Parkinson’s disease (Naidoo et al., 2014), concussive blast injury
(Yin et al., 2014), protection of cultured cells from doxorubicin-
mediated activity (Figure 1), and rebound of NAD levels in doxo-
rubicin-treated cells (Table S1).
Finally, we tested whether the recombinant NAMPT enzyme
couldbephotocrosslinked toP7C3-S326. As shown in FigureS7,
P7C3-S326 binds directly to NAMPT in a manner competed
by active variants of P7C3 (P7C3-A20 and P7C3-S243), but
not by the inactive P7C3-S87 variant.
DISCUSSION
Why is it that active variants of P7C3 are able to protect cultured
cells from doxorubicin-mediated toxicity, in the face of no pro-
tective activity against seven other toxins? Three observations
now help understand this selectivity. First, doxorubicin reducesCell 158, 1324–1334, Sepintracellular levels of NAD, likely via acti-
vation of PARP. Second, active variants
of P7C3 protect cultured cells from
dox:tox, likely by stimulating a rebound
in the intracellular levels of NAD. Third,
active variants of P7C3 enhance the ac-
tivity of the purified, recombinant NAMPT
enzyme. We conclude that the dox:tox
protective activity of our aminopropyl
carbazole chemicals is directly reflective
of their ability to enhance the salvage
pathway whereby nicotinamide is con-
verted to NAD. Our findings are consis-
tent with earlier reports that programmedenhancement in the expression of the NAMPT enzyme protects
mammalian cells against genotoxic stress (Yang et al., 2007) and
extends the life span of budding yeast (Anderson et al., 2002).
The target-agnostic in vivo screen performed years ago led, in
an unbiasedmanner, to the P7C3 class of neuroprotective chem-
icals (Pieper et al., 2010).We now hypothesize that the neuropro-
tective efficacy of our aminopropyl carbazole chemicals can be
attributed to their ability to foster salvage of NAD from nicotin-
amide. This interpretation is concordant with an equally unbiased
series of forward genetic studies performed over the past three
decades. In the 1980s, scientists working in Oxford, England
described a variant strain of mice that impedesWallerian degen-
eration, designated theWallerian degeneration slow (wlds) strain
(Lunn et al., 1989). In simple terms, Wallerian degeneration can
be described as the demise of axonal processes distal from the
cell body to a site of nerve crush. Axons of wlds mice survive atember 11, 2014 ª2014 Elsevier Inc. 1329
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Figure 6. P7C3-A20 Enhances the Flux of
Nicotinamide through the Salvage Pathway
(A) Cells were pretreated with 0.5 mM doxorubicin
for 48 hr, followed by 6 hr treatment with 14C-
nicotinamide in the presence of the indicated
amount of P7C3-A20. Metabolites were extracted
and analyzed by thin-layer chromatography (a
representative result from three experiments is
shown here). Free 14C-nicotinamide was loaded
(the first lane) as a standard.
(B) Quantification of the relative intensities of NAD
and NMN from the thin-layer chromatogram.nerve crush far longer than those of wild-type mice. The wlds
gene was positionally cloned in the 1990s and found to exist as
a triplicated fusion gene encoding the first 70 amino acids of
Ufd2a, a ubiquitin-chain assembly factor, linked directly to the
complete coding sequence of NMNAT1 (Coleman et al., 1998;
Conforti et al., 2000;Mack et al., 2001).WhereasNAMPT initiates
salvage fromnicotinamide,NMNAT1 is one of three enzymes that
convert the NMN intermediate into NAD.
In a seminal paper published in 2004 in Science, Dr. Jeff
Milbrandt and colleagues provided evidence that the wlds
phenotype can be attributed primarily to the overexpression of
NMNAT1 (Araki et al., 2004). The closing sentence of their manu-
script is unusually prescient, reading ‘‘It is possible that the alter-
ation of NAD levels by manipulation of the NAD biosynthetic
pathway, Sir2 protein activity, or other downstream effectors
will provide new therapeutic opportunities for the treatment of
diseases involving axonopathy and neurodegeneration.’’ We
offer the conclusion that this is exactly what active variants of
the P7C3 category of neuroprotective drugs do—they enhance
the intracellular production of NAD by agonizing the activity
of the rate-limiting enzyme in the NAD salvage pathway.
It has recently been reported that NAD production attenuates
as a function of aging in the hippocampus of rodents (Stein and
Imai, 2014). The latter study further reported age-related decline
in the expression of NAMPT in the hippocampus, along with
evidence that selective elimination of the NAMPT gene in
neuronal stem cells significantly impairs hippocampal neurogen-
esis. Now that we understand that active members of the P7C3
class of compounds function by enhancing the activity of the
NAMPT enzyme, the observations of Stein and Imai lend credi-
bility to our original discovery of P7C3 as a chemical stimulant
of hippocampal neurogenesis.
In addition to offering progress toward an understanding of the
mode of action of the P7C3 class of neuroprotective chemicals,
this work also points to a number of important, unanswered
questions. First and foremost, where on the NAMPT enzyme do
our chemicals bind, and how do they facilitate agonistic activa-
tion? Given that there are only about a dozen known examples
of allosteric chemical activators of enzymes (Zorn and Wells,
2010), understanding the mechanism of NAMPT activation by
P7C3 represents an important challenge for future studies. Sec-
ond, why is it that covalent binding of P7C3-S326 causesNAMPT
tomigrate in an anomalousmanner in SDS-PAGEgels? Third, is it
indeed the case that NAD levels may be compromised as a func-1330 Cell 158, 1324–1334, September 11, 2014 ª2014 Elsevier Inc.tion of nerve cell injury or neuronal dysfunction as a consequence
of neurodegenerative disease? Fourth, might NAMPT be regu-
lated in vivo by an endogenousmetabolite that is eithermimicked
or counteracted by active variants of the P7C3 class of neuropro-
tective chemicals? Fifth, is it possible that the modest levels of
compound-elevated activation of the purified, recombinant
NAMPT enzyme can account for the full in vivo efficacy of active
variant of the P7C3 class of neuroprotective chemicals? Several
arguments may be invoked to speculate on this question. For
example, it is possible that P7C3 displaces the function of an
inhibitory metabolite within the cell or that the native NAMPT
enzyme is regulated by posttranslational modification, intracel-
lular localization, or any of a wide spectrum of variables not re-
constituted in the context of the purified, recombinant enzyme.
Weclosewith twoobservations thatmayormaynot be related.
Studies of aged mice have led to the reported decline in tissue
NAD levels and that certain aspects of age-related decline in
overall health can be reversed by nutritional supplementation of
NMN (Gomes et al., 2013). In our initial studies of P7C3, we re-
ported compound-mediated abrogation in cognitive decline in
aged Fisher rats (Pieper et al., 2010). Included in such studies
was the unanticipated observation that compound-treated rats
maintained body weight relative to the frailty of vehicle-treated
controls. Thesedistinct studiesoffer thepossibility of considering
the P7C3 class of neuroprotective chemicals as potential treat-
ments for generalized frailty typical of aged animals and humans.
EXPERIMENTAL PROCEDURES
Neurogenesis Measurement
Neurogenesis in mouse hippocampus was measured as previously described
(Pieper et al., 2010). The animal experiments were approved by the University
of Texas Southwestern Medical Center Institutional Animal Care and Use
Committee.
Cell Culture
Osteosarcoma cell line U2OS cells were grown in Dulbecco’smodified Eagle’s
medium (Sigma) supplemented with 10% fetal bovine serum (FBS). Lung can-
cer cell line H2122 cells were cultured in RPMI-1640 medium (HyClone) sup-
plemented with 5% FBS. These adherent cell lines were cultured employing
standard procedures.
Cell Survival Assay
Cell survival assay was performed in 96-well plates using CellTiter-Glo Lumi-
nescent Cell Viability Assay kit (Promega) that measures cellular ATP content.
The CellTiter-Glo reagent was diluted by adding two volumes of PBS
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Figure 7. Active Variants of P7C3 Enhance
the Activity of Purified NAMPT Enzyme
(A) P7C3-A20 was incubated at indicated con-
centrations in a reaction coupled with three
enzymes: NAMPT, NMNAT, and ADH (Experi-
mental Procedures). NAMPT activity was re-
corded for the indicated period of time at
OD340 nm by measuring NADH appearance,
leading to the indicated concentration-time plot.
Each assaywas repeated three independent times
with similar results. See also Figure S6.
(B) Analysis of the activities of 30 P7C3 analogs
was performed to assess their effects on NAMPT
enzymatic activity. The reaction rate was calcu-
lated as the slope of the concentration-time curve.
Relative reaction rate was normalized by the
control reaction run prior to compound addition.
Data represent the mean of experimental dupli-
cates. Scatter graphs were plotted to compare the
ability of compounds to activate NAMPT relative to
their ability to compete away P7C3-S326 cross-
linking (top scatterplot), ability to protect cells from
doxorubicin-mediated toxicity (middle scatter-
plot), or ability to facilitate NAD restoration in
doxorubicin-treated cells (bottom scatterplot).
Significant correlations were observed from all
three sets of data. See also Table S1.
(C) Comparison of P7C3-S243 enantiomers
showed that ()-P7C3-S243 was superior to
(+)-P7C3-S243 in activating the purified NAMPT
enzyme. Data are expressed as mean ± SD of
duplicate independent assays. See also Figure S7.containing 1% Triton X-100. Fifty microliters of diluted reagent was directly
added to 100 ml of cell culture medium per well. The plates were incubated
at room temperature for 10 min. Luminescence was recorded by Tecan
SPECTRAFluor Plus reader (Tecan). Cell survival was presented as the per-
centage of viable cells compared with untreated control, and mean ± SD
was calculated from duplicates. The dox-tox assay of P7C3 analogs was car-
ried out in the HTS Core (University of Texas Southwestern Medical Center)
using EnVison multimode plate reader (PerkinElmer).
Chemical Synthesis of Photocrosslinking Probe P7C3-S326
N-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-fluoropropyl)-4-(4-(prop-2-yn-1-yloxy)
benzoyl)benzamide (P7C3-S326).Cell 158, 1324–1334, Sep3-(3,6-dibromo-9H-carbazol-9-yl)-2-fluoropro-
pan-1-amine (Naidoo et al., 2014; 40.2 mg;
0.10 mmol) was added to a solution of 4-(4-
(prop-2-yn-1-yloxy)benzoyl)benzoic acid (Ban-
dyopadhyay and Bong, 2011; 28.5 mg; 0.10
mmol), N-(3-dimethylaminopropyl)-N0-ethylcarbo-
diimide hydrochloride (21.2 mg; 0.11 mmol),
and 1-hydroxybenzotriazole hydrate (15.0 mg;0.11 mmol) in dimethylformamide (0.4 ml). The reaction went to completion
within 1 hr. The mixture was diluted with EtOAc and washed several times
with water and then brine. The organic layer was dried over Na2SO4, filtered,
and condensed to give a light brown solid in 90% yield. 1H nuclear magnetic
resonance (NMR) signals in acetone-d6 at 400 MHz were as follows: d 8.41
(dd, J = 2.0, 0.6 Hz, 2H), 8.07 (d, J = 8.4 Hz, 2H), 7.82 (dd, J = 10.3, 8.6 Hz,
4H), 7.71–7.56 (m, 4H), 7.16 (d, J = 8.9 Hz, 2H), 5.39–5.10 (dm, 1H), 4.94
(d, J = 2.4 Hz, 2H), 4.91–4.85 (m, 1H), 4.82 (d, J = 5.4 Hz, 1H), 4.05–3.89
(m, 1H), 3.87–3.70 (m, 1H), and 3.17 (t, J = 2.4 Hz, 1H). 13C NMR signals in
CD2Cl2 at 100 MHz were as follows: 194.6, 167.3, 161.7, 141.4, 140.1,
136.9, 132.8, 130.7, 130.2, 129.7, 127.3, 124.1, 123.6, 114.9, 113.0, 111.2
(JC–F = 1.9 Hz), 92.1 (JC–F = 176.2 Hz), 78.2, 76.3, 56.4, 45.8 (JC–F =
22.5 Hz), and 42.3 (JC–F = 21.2 Hz). The mass spectrum of P7C3-S326
showed an m/z of 660.7 under electrospray ionization, which corresponds to
[M+1]+. The calculated value is calculated 660.01.
Live-Cell Crosslinking with Photocrosslinking Derivative S326
S326 was diluted to 0.3 mM in culture medium to treat H2122 cells. After incu-
bation at 37C for 2 hr, H2122 cells were irradiated for 15 min under 306 nm
ultraviolet light in a Stratalinker 2400 (Stratagene). Cells were then harvested
by dissolving in 1% SDS lysis buffer (50 mM HEPES [pH 8.0], 2 mM MgCl2,
10 mM KCl, 1% SDS, 50 units/ml of Benzonase [Sigma], supplemented with
Sigmafast protease inhibitor [Sigma]).tember 11, 2014 ª2014 Elsevier Inc. 1331
Attachment of Fluorescent Tags via CUAAC CLICK Reaction
For copper-catalyzed azide-alkyne cycloaddition (CUAAC) CLICK reactions,
43 ml of SDS lysate was mixed with 3 ml of 1.7 mM Tris[(1-benzyl-1H-1,2,3-
triazol-4-yl)methyl]amine, 2 ml of 50 mM CuSO4, 1 ml of 50 mM Tris(2-
carboxyethyl)phosphine, and 1 ml of 1.25 mM Alexa 532 azide. The reaction
was incubated at room temperature with constant agitation at 1,000 rpm on
a thermomixer (Eppendorf) for 1 hr. Afterward, samples were mixed with
SDS sample-loading buffer and loaded on an 8% SDS-PAGE gel, separated,
and imaged using a Typhoon imager (filter settings: excitation 533 nm, emis-
sion 555 nm, and high sensitivity).
In Vivo Binding Competition Assay
H2122 cells were incubated with the S326 (0.3 mM) in the absence or presence
of 5 mM P7C3 analogs for 2 hr following by UV crosslinking in vivo. Cells were
lysed in 1% SDS lysis buffer, and lysates were conjugated to the fluorescent
Alexa 532 dye using CLICK reaction. The samples were run on SDS-PAGE,
and the gel was scanned using a Typhoon Imager. The p70 band intensity
was analyzed and quantified by Image J, and the relative intensity in each
assay was normalized to that of the DMSO control.
2D Gel Electrophoresis
H2122 cells were incubated with S326 (0.3 mM) in the absence or presence of
5 mMof the active analog A20 for 2 hr followed by UV crosslinking in vivo. Cells
were dissolved in 1% SDS lysis buffer, and protein concentration was quanti-
fied by the bicinchoninic acid assay. For CLICK reactions, 1 mg of lysates pre-
pared from S326-treated cells were reacted with Alexa 532 azide (red), and
1 mg of lysates from S326- and A20-treated cells were reacted with Cy5 azide
(green). After the CLICK reaction, the two lysates were combined together,
mixed with four volumes of acetone, and incubated at 20C overnight.
Precipitated proteins were collected by centrifugation at 8,000 g, 15 min,
4C. After two washes with acetone, the pellet was air dried and resuspended
in 500 ml of 2D rehydration buffer (8 M urea, 2% 3-[(3-cholamidopropyl)dime-
thylammonio]-1-propanesulfonate hydrate [w/v], 50 mM dithiothreitol [DTT],
and 2% of immobilized pH gradient [IPG] buffer). For 2D gel electrophoresis,
500 mg of proteins were loaded onto IPG strip of 24 cm (pH 3–10) linear (GE
Healthcare) by passive rehydration using rehydration chamber for overnight
at room temperature. Isoelectric focusing was conducted on an IPG Phor3
manifold (GE Healthcare) with the following protocol: 100 V for 3 hr, 300 V
for 2 hr, 500 V for 3 hr (step-and-hold); 1,000 V for 1 hr (gradient); 8,000 V for
3 hr (gradient); and 8,000 V for 4 hr (step-and-hold) with total 42,000 V/hr. After
isoelectric focusing, the strip was equilibrated for 15 min in equilibration buffer
I (6 M urea, 2% SDS [w/v], 0.375 M Tris [pH 8.8], 20% glycerol [v/v], and
100 mM DTT) for 15 min followed by equilibration buffer II (6 M urea, 2%
SDS [w/v], 0.375 M Tris [pH 8.8], 20% glycerol [v/v], and 250 mM iodoaceta-
mide) for 15 min. Proteins were separated in the second dimension on 7.5%
SDS-PAGE using Ettan Daltsix unit (GE Healthcare) at a constant current of
40 mA/gel for 5 to 6 hr at 100 W. Gel images were scanned at a resolution of
100 mm on Typhoon FLA9500 scanner using default settings for CyDyes (GE
Healthcare) and preprocessed using Image Quant TL software v8.1 (GE
Healthcare). Cropped gel images were analyzed using DeCyder2D Differential
Analysis Software v7.1 (GE Healthcare) to detect, normalize, and quantify the
protein features in the images. The P7C3-A20-competed green spots and
several background spots were identified and robotically excised by an Ettan
Spot Picker (GE Healthcare).
Mass Spectrometry for Protein Identification
Gel pieces were washed using 50 mM triethylammonium bicarbonate (TEAB)
(pH 8.0) in 50% (v/v) acetonitrile followed by reduction with 20 mM DTT and
alkylation with 55 mM iodoacetamide. Gel pieces were dehydrated using
100% (v/v) acetonitrile, air dried, and then rehydrated in the presence of
250 ng of sequencing grade trypsin (Sigma) in 50 mM TEAB. Digests were
allowed to proceed overnight at 37C. Mass spectrometry was performed
using Q Exactive mass spectrometers (Thermo Fischer; Bremen), coupled
to identical Ultimate 3000 RSLCnano HPLC systems (Dionex). Peptides
were loaded onto a 75 mm inner diameter 3 50 cm Thermo Scientific Easy-
Spray column packed with 2 mm resin. A 40 min linear gradient of 1%–28%
acetonitrile in 0.1% formic acid followed by a 10 min ramp to 98% acetonitrile,1332 Cell 158, 1324–1334, September 11, 2014 ª2014 Elsevier Inc.using a flow rate of 350 nl/min, was employed to elute peptides from the
column. The Easy Spray column was heated to 55C using the integrated
heater. Higher-energy C-trap dissociation analyses were performed on the
Q Exactive instrument using a data-dependent top 20 method, with the full
mass spectrometry (MS) scans acquired at 70 K resolution (at m/z 200) and
MS/MS scans acquired at 17.5 K resolution (at m/z 200). The underfill ratio
was set at 0.1%, with a 3 m/z isolation window and fixed first mass of
100 m/z for the MS/MS acquisitions. Charge exclusion was applied to exclude
unassigned and charge 1 species, and dynamic exclusion was used with
duration of 15 s.
Measurement of Intracellular NAD Abundance
By Liquid Chromatography-MS
Cellular metabolites were extracted using 50% methanol by multiple freeze-
thaw cycles. The cleared metabolites were dried in a Speed-Vac. The dried
materials were dissolved in 0.1% formic acid and subjected to mass spectro-
metric analysis using a specific method developed for NAD. Relative intracel-
lular NAD levels (NAD ion counts divided by total ion counts) were used for
intersample comparisons.
By NAD/NADH-Glo Assay Kit
The assay was performed following the manufacturer’s protocol (Promega).
NAD/NADH-Glo reagent contains the NAD cycling enzyme that converts
NAD+ to NADH. In the presence of NADH, the enzyme reductase reduces a
proluciferin reductase substrate to form luciferin. Cells were grown in 96- or
384-well plates. Fifty microliters or 15 ml of NAD/NADH-Glo Detection
Reagent were added to each well. The resulting luminescence signals
were measured by Tecan plate reader or EnVison multimode plate reader
(PerkinElmer).
Nicotinamide Flux Analysis with 14C-Labeled Nicotinamide
Logarithmically growing cells cultured in 6-well plates were treated with doxo-
rubicin (0.5 mM) for 48 hr. Afterward, 1 ml of 0.5 mCi/ml 14C nicotinamide (spe-
cific activity: 50 mCi/mmol; American Radiolabeled Chemicals) were added
per well. The cells were then washed once with PBS and collected by trypsin
digestion. Metabolites were extracted from cells with 50 ml of perchloric acid
(0.5 M) by incubating on ice for 20 min. The extracts were then neutralized
with 13.75 ml of KCl/KOH (0.5 M/2.0 M) and centrifuged at 2500 3 g for
10 min at 4C. Ten microliters of extracted metabolites were separated and
identified using silicon thin-layer chromatography plates with 1 M ammonium
acetate:ethanol (3:7) as solvent. For autoradiography, the chromatograms
were exposed to storage Phospho screen for 3 days. Afterward, the screen
was scanned using the Typhoon scanner and the 14C-labeled compounds
were quantified using Image J.
In Vitro NAMPT Assay
The NAMPT activity was determined by a coupled enzyme spectrometric
assay as described by Khan et al. (2006) with minor modifications. Briefly,
NAMPT first converted nicotinamide to NMN, which was followed by sequen-
tial production of NAD via the NMNAT. NAD was then reduced to NADH by
alcohol dehydrogenase (Sigma) using alcohol as the substrate. The resulting
NADH was monitored by optical density (OD) 340 nm. Human NAMPT and
NMNAT were overexpressed in E. coli and purified as described by Wang
et al. (2006) and Zhou et al. (2002), respectively. The reaction mixture con-
tained 50 mM Tris (pH 8.0), 0.4 mM phosphoribosylpyrophosphate (Sigma),
2.5 mM ATP, 12 mM MgCl2, 1.5% (v/v) ethanol, 10 mM semicarbazide
(Sigma), 0.02% (w/v) BSA, 2.4 mg/ml NMNAT, 0.4 unit alcohol dehydroge-
nase, 1 mMNAMPT, and 150 mM nicotinamide. Ten micromolar P7C3 analogs
in DMSO were further diluted in ethanol prior to applying to the reaction. To
minimize variation, a control reaction was run in each assay prior to com-
pound addition.
Statistics
The correlation data analysis was performed in GraphPad Prism 6. All p values
were obtained using Spearman Rank Correlation (v1.0.1) in Free Statistics
Software (v1.1.23-r7), Office for Research Development and Education
(http://www.wessa.net/rwasp_spearman.wasp).
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